Comparison between Glenmark Life Sciences IPO and Tatva Chintan Pharma Chem IPO.
Glenmark Life Sciences IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Tatva Chintan Pharma Chem IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Glenmark Life Sciences IPO is up to ₹1,513.60 Cr whereas the issue size of the Tatva Chintan Pharma Chem IPO is up to ₹500.00 Cr. The final issue price of Glenmark Life Sciences IPO is ₹720.00 per share and of Tatva Chintan Pharma Chem IPO is ₹1,083.00 per share.
| Glenmark Life Sciences IPO | Tatva Chintan Pharma Chem IPO | |
|---|---|---|
| Face Value | ₹2 per share | ₹10 per share |
| Issue Price (Lower) | ₹695.00 per share | ₹1,073.00 per share |
| Issue Price (Upper) | ₹720.00 per share | ₹1,083.00 per share |
| Issue Price (Final) | ₹720.00 per share | ₹1,083.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ||
| Market Lot Size | 20 shares | 13 shares |
| Fresh Issue Size | 1,47,22,222 shares | 20,77,562 shares |
| Fresh Issue Size (Amount) | up to ₹1,060.00 Cr | up to ₹225.00 Cr |
| OFS Issue Size | 63,00,000 shares | 25,39,242 shares |
| OFS Issue Size (Amount) | up to ₹453.60 Cr | up to ₹275.00 Cr |
| Issue Size Total | 2,10,22,222 shares | 46,16,804 shares |
| Issue Size Total (Amount) | up to ₹1,513.60 Cr | up to ₹500.00 Cr |
Glenmark Life Sciences IPO opens on Jul 27, 2021, while Tatva Chintan Pharma Chem IPO opens on Jul 16, 2021. The closing date of Glenmark Life Sciences IPO and Tatva Chintan Pharma Chem IPO is Jul 29, 2021, and Jul 20, 2021, respectively.
| Glenmark Life Sciences IPO | Tatva Chintan Pharma Chem IPO | |
|---|---|---|
| Anchor Bid Date | Jul 26, 2021 | Jul 15, 2021 |
| Issue Open | Jul 27, 2021 | Jul 16, 2021 |
| Issue Close | Jul 29, 2021 | Jul 20, 2021 |
| Basis Of Allotment (Tentative) | Aug 03, 2021 | Jul 26, 2021 |
| Initiation of Refunds (Tentative) | Aug 04, 2021 | Jul 27, 2021 |
| Credit of Share (Tentative) | Aug 05, 2021 | Jul 28, 2021 |
| Listing date (Tentative) | Aug 06, 2021 | Jul 29, 2021 |
| Anchor Lockin End date 1 | Sep 02, 2021 | Aug 25, 2021 |
| Anchor Lockin End date 2 | Nov 01, 2021 | Oct 24, 2021 |
Glenmark Life Sciences IPO P/E ratio is , as compared to Tatva Chintan Pharma Chem IPO P/E ratio of .
| Glenmark Life Sciences IPO | Tatva Chintan Pharma Chem IPO | |||||
|---|---|---|---|---|---|---|
| Financials | Company Financials ()
| Company Financials ()
| ||||
| Promoter Shareholding (Pre-Issue) | 100 | 100 | ||||
| Promoter Shareholding (Post-Issue) | 82.84 | 79.17 | ||||
| P/E Ratio | ||||||
| Market Cap | ₹8821.96 Cr. | ₹2400.48 Cr. | ||||
| ROE | ||||||
| ROCE | ||||||
| Debt/Equity | ||||||
| EPS | ||||||
| RoNW |
In the Glenmark Life Sciences IPO Retail Individual Investors (RII) are offered 73,57,778 shares while in Tatva Chintan Pharma Chem IPO retail investors are offered 73,57,778 shares. Qualified Institutional Buyers (QIB) are offered 42,04,450 shares in Glenmark Life Sciences IPO and 9,23,361 shares in Tatva Chintan Pharma Chem IPO.
| Glenmark Life Sciences IPO | Tatva Chintan Pharma Chem IPO | |
|---|---|---|
| Anchor Investor Reservation | 63,06,660 shares | 13,85,040 shares |
| Market Maker Reservation | ||
| QIB | 42,04,450 shares | 9,23,361 shares |
| NII | 31,53,334 shares | 6,92,521 shares |
| RII | 73,57,778 shares | 16,15,882 shares |
| Employee | ||
| Others | ||
| Total | 2,10,22,222 shares | 46,16,804 shares |
Glenmark Life Sciences IPO subscribed 44.17x in total, whereas Tatva Chintan Pharma Chem IPO subscribed 180.36x.
| Glenmark Life Sciences IPO | Tatva Chintan Pharma Chem IPO | |
|---|---|---|
| QIB (times) | 36.97x | 185.23x |
| NII (times) | 122.54x | 512.22x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 14.63x | 35.35x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 44.17x | 180.36x |
